Roivant Q1 loss widens to $0.33/share; completes $1.5B buyback, initiates new $500M program

Roivant Sciences Ltd.

2025-Q1 EPS reported -$0.33 revenue$2,170,000

GAAP loss from continuing ops $273.9M ($0.33/share) vs income $31.6M ($0.01) YoY; revenue $2.2M down from $8.0M.
Non-GAAP loss from continuing ops $170.1M vs $107.1M YoY; R&D spend up $32.4M to $152.9M.
Completed $1.5B share repurchase program; board approved new $500M buyback in June 2025.
Cash, equivalents, restricted cash and marketable securities $4.5B; shares outstanding reduced >15% from Mar 2024.
Brepocitinib VALOR DM Phase 3 topline data H2 2025 (LPLV July); IMVT-1402 registrational trials started in GD, SjD June.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.